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Executive Summary 
 
Transdermal drug delivery systems have been developed over the past several decades and 
now include patches for birth control, nicotine addiction, and pain relief.  The local application of 
heat can increase the diffusion coefficient of the drug in the skin and result in faster delivery of 
the  drug  and  shorter  time  to  reach  a  steady  state  concentration  of  the  drug.    While  this 
procedure is desirable for some systems where a faster dose will aid in alleviating pain and/or 
symptoms, it can also be a cause of concern for some drugs.  Fentanyl, a chronic pain relief 
drug, can cause accidental death by overdose.  We report herein an analysis of the effects of 
various  heating  situations  on  transdermal  fentanyl  delivery  based  upon  a  model  developed 
using COMSOL Multiphysics.  The utilization of such a model allows for the determination of 
situations  which  may  be  potentially  dangerous  for  fentanyl  drug  users,  and  enables  the 
development  of  usage  guidelines  and  safety  mechanisms  for  transdermal  delivery  systems.  
Using the computer model, the following cases were simulated: no applied heat, ThermaCare 
heat  pad,  fever,  and  heating  blanket.    The  heating  blanket  and  ThermaCare  heat  pad 
simulations showed the most dangerous increases in fentanyl blood concentration above no-
heat levels: about 180% and 100%, respectively, over 30 hours; by contrast, the patient fever 
model reported a 40% increase in fentanyl blood concentration.  These simulations demonstrate 
the dangers of fentanyl transdermal pain patches when skin temperature is increased, and can 
be used to develop better patient guidelines for patch use and to improve fentanyl transdermal 
systems.  Lastly, this computer model may be used to model other transdermal drug delivery 
systems for the improvement of patient guidelines and/or the development of new systems, thus 
decreasing the need for experimentation on subjects. 
Key words:  transdermal, drug delivery, fentanyl 
 
Introduction and Design Objectives 
The increasing popularity and market of transdermal drug delivery systems, in the form of a skin 
patch,  has  resulted  in  several  commercially  available  products  ranging  from  birth  control  to 
nicotine addiction to pain relief.  Such patches are designed to give an appropriate drug dose 
over  a  given  time  at  body  temperature.    Directly  applied  heat  or  otherwise  raised  body 
temperature can increase the diffusivity of the drug from the transdermal system in the skin and 
result in a higher dose of drug over the same time, leading to potentially adverse effects.   This 
report  focuses  on  the  effects  of  local  heat  applied  when  using  a  fentanyl  pain  patch.    The 
fentanyl  patch  is  of  particular  interest  due  to  the  fact  that  there  have  been  numerous 
documented cases of accidental overdose when using the transdermal delivery system.  Many 
of these overdoses were caused by perturbations of body temperature created by deliberate or 
unintentional heating of the body or the area with the patch.   
 
While several drugs that are currently marketed as transdermal systems can cause adverse 
effects when a certain dose threshold is surpassed over a given time, fentanyl is of particular 
concern due to its potential lethal effects that can result from such an overdose.  Fentanyl is 4 
 
 
used as an analgesic and an anesthetic, typically in the operating room.  First synthesized by 
Janssen Pharmaceutica (Belgium) in 1959, fentanyl is an opioid analgesic that is eighty times 
more potent than morphine.  Transdermal delivery systems release the drug through the skin 
and into fat where it can then be released continuously over a longer period to treat chronic 
pain.  However, even correctly designed patches may allow overdose when external heat is 
applied and increases the diffusivity of fentanyl in the skin.  Incidents of such overdoses have 
been documented when patients applied heat to the patch area in order to treat an acute pain 
attack.  The dangers of fentanyl overdose as a result of heat addition have been extensively 
documented. One published case reported respiratory failure in a patient undergoing surgery; 
the cause was found to be fentanyl overdose as a result of a heating blanket being put on the 
patient,  who  was  wearing  a  fentanyl  patch.
i  Additionally,  the  FDA  has  issued  a  warning 
regarding the potential for accidental fentanyl overdose when heat is applied to the patch, either 
directly or indirectly. The FDA   notes that overdoses may result in  dangerous  side-effects, 
including  respiratory  failure,  drowsiness,  dizziness,  nausea,  confusion,  an xiety,  vomiting, 
itching, or even death.
ii 
Our simulation demonstrated a significant increase in fentanyl dosage when a  heating blanket 
and ThermaCare heat pad w ere applied to the skin surface during the  30 hour time period  
analyzed  (typical duration of patch use) .  Despite even detailed warnings prescribed with 
transdermal drug delivery systems, the risk of overdose when using a transdermal drug delivery 
system is still a concern.  We propose the use of computer simulation of drug d iffusion with 
varying heat application  to develop better, quantitative guidelines that address the risks of 
elevated body temperature when using transdermal drug delivery systems and to design such 
systems with possible safety mechanisms to protect patients against overdose.  The goal of this 
project  is  to  model  the  Duragesic  fentanyl  transdermal
iii  delivery  system  using  COMSOL 
Multiphysics.  By developing a model of the transport properties of fentanyl through  two layers 
of the skin (epidermis and dermis), the effects of local applied heat on the diffusion of fentanyl in 
the skin can be analyzed.  Additionally, such a model can be used to determine guidelines for 
patients using the Duragesic patch.  Such a model could also easily be used to examine other 
transdermal drug delivery systems including motion sickness and birth control.   This report will 
guide the reader through the development of a computer model of fentanyl diffusion, beginning 
with the governing equations  and physics from which the model was bui lt.  The model will be 
tested in four different scenarios, one in which a heating pad is applied (ThermaCare  brand), 
one in which the patient has a fever (102º F), one in which a heating blanket (42º C or 107.6ºF) 
is covering the patient, and a control case in which no local heat is applied.  By analysis of the 
results from these scenarios, the increase of drug delivery attributable to local applied heat will 
be determined.  Through this analysis, guidelines for use of fentanyl patches and similar 
transdermal drug delivery systems in re gard to local applied heat and safety concerns  will be 
discussed in addition to possible design considerations.    
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*Temperature profile as given by Figure 4. 
Figure  1.  Schematic  of  system  and  skin  with  boundary  conditions  and  appropriate 
geometry.  The hypodermis layer was not included in the COMSOL model since fentanyl 
uptake occurs in the dermis.  Not drawn to scale.   
 
Model Design 
In order to assess the effects of applied heat on transdermal drug delivery systems, COMSOL 
Multiphysics was used to create a simulation tool to evaluate these drug delivery systems in 
response to various methods of heating.  The model geometry (Figure 1) encompasses two 
layers of skin (epidermis and dermis).  A small section of skin outside the radius of the patch 
was also included in the model to determine the amount of lateral diffusion of the drug within the 
skin layers.  The heating elements were modeled as covering the patch as well as the additional 
section of the skin on the side of the patch.   The geometry and size of the fentanyl patch 
modeled was chosen after review of several common, commercially available fentanyl patches.  
The circular geometry of the path permitted the use of two-dimensional axisymmetric model to 
reduce computation.  A constant concentration of fentanyl at the skin surface was used as the 
transdermal patch is designed to maintain a constant concentration over a period of 72 hours 
(length of time before patch should be replaced). 
Our model is designed to report fentanyl blood concentration over time, based upon the ability 
of fentanyl to diffuse through human skin.  The diffusivity of fentanyl in skin is given by the 
Arrhenius relation for diffusion, which relates diffusivity to skin temperature.  It is this relation 
upon which the diffusivities of the epidermis and dermis layers in our model were based. 
Our model was designed to match data from a study by Ashburn, et al., in which subjects were 
periodically tested for fentanyl blood concentration following application of a fentanyl patch.  In 
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one experiment, subjects wore the patch for 24 hours without heat addition, and then one hour 
of heat from a heat pad (42º C) was applied to the patch, followed by five hours without heat.  
Our model was first compared with the experimental data for the 24-hour period in which no 
heat was added; our data is shown below on the right. 
 
Figure 2. Comparison of model to experimental data: fentanyl blood concentration over 
24 hours with no applied heat. 
We multiply the model’s blood concentration value of 2.8E-6mol/m
3 by the molecular weight of 
fentanyl (336.5g/mol) and divide by 10
6ml/m
3 to obtain a value of 0.942ng/ml.  This value is very 
similar to the 0.9ng/ml recorded in the experiment
iv. 
Our model further considers the effect of temperature on the diffusion coefficient for fentanyl in 
skin, which is given by the Arrhenius relation for diffusion.  All else equal, the Arrhenius relation 
should account for any changes in diffusivity due to temperature; however, studies have shown 
that an increase in skin temperature from 32ºC to 40ºC can increase the cutaneous blood flow 
10-15 times.  This effect has been shown to dramatically increase the rate of drug flux into the 
bloodstream.
v  To account for this, a term was added to the diffusivity equation for the dermis 
layer to mimic the effects of increased blood convection on fentanyl diffusion.   The term was 
designed to amplify changes in diffusivity resulting from increases in temperature.  The general 
forms of the equations used in both the epidermis and dermis layers are given below: 
 
  Epidermis:      
  Dermis:      
*Values of coefficients in the above equations may be found in the Appendix.   
Added term 7 
 
 
Previous experimental studies have suggested that the diffusivity of the dermis is 400 times that 
of the epidermis at body temperatures.
vi  By comparing our simulation to experimental data that 
included  applied  heat,  it  was  determined  that  the  difference  in  diffusivities  between  the 
epidermis and the dermis that was amplified 400 times  when heat is applied instead of 400 
times the diffusivity at body temperature.   The multiplicative factor of 400 in the added term 
shown above was tailored to match experimental data.  Our model’s data is shown below. 
                                    
Figure 3. Comparison of model to experimental data: fentanyl blood concentration over 
30 hours with one hour of applied heat at 24 hours. 
The graph above shows blood concentration of fentanyl measured over a 30-hour period.  Our 
model incorporated the same heating curve used in the experimental study
vii.  It was found that 
the aforementioned relationship  yielded the greatest similarity between our model and the 
experimental study to which it was compared, with the peak values being the same. 
In order to develop a temperature profile over time to model localized heat by a heating pad, we 
collected data on the temperature profile of skin surface temperature while using a common 
commercial instant heating pad (data shown below). 
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Figure 4.  Skin temperature over time while using a ThermaCare heat pad on the arm 
(experimental data). 
Using a ThermaCare heating pad and a thermocouple the values of temperature over time at 30 
second invervals for a total of 20 minutes were measured.  This data was then applied to our 
model for interpolation of temperature over time.  The ThermaCare heating pad is advertised to 
remain at its equilibrium temperature for at least eight hours which was also verified by our 
experimental study.  Since our model analyzes drug delivery from the transdermal patch for six 
hours, the equilbrium skin surface temperature reached after 20 minutes was interpolated to the 
six hour time point.  The experimental data used is subject to error of several forms, including 
movement of the thermocouple, uneven distribution of heating elements within the pad, and 
measurement error.  ThermaCare heating pads develop uneven heating of the pad as a whole 
due to the fact that the pad consists of several heating elements interspersed throughout the 
pad, as opposed to a uniform distribution of heating elements.  The experimental data was 
measured with the thermocouple against the skin in between two of these heating elements as 
opposed to directly touching a heating element. 
 
Results and Discussion     
The  computer  simulation  described  in  this  report  was  used  to  model  fentanyl  blood 
concentration in several situations in which elevated body temperature occurs.  Drug uptake into 
the bloodstream does not begin until the drug reaches the vascular network in the dermis layer 
of the skin.  To calculate fentanyl blood concentration, a function was written that integrated the 
total fentanyl flux through the bottom layer of the dermis.  Fentanyl blood concentrations could 
then be compared to the control case (no heat) and described as percent increases (shown in 
Figure 9), which are more relevant for discussion given the numerous variables that dictate 
necessary,  dangerous,  and  lethal  fentanyl  blood  concentrations  (age,  weight,  duration  of 
fentanyl use, etc.) from patient to patient.  
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The computer model was used to simulate the concentration profile of fentanyl in the skin over 
30 hours both with and without applied local heat, modeled with experimental data obtained 
from a ThermaCare heat pad, heating blanket temperatures, and elevated body temperatures 
resulting from fever.  As seen in Figures 8-9, the continuous application of a ThermaCare heat 
pad increased the blood concentration of fentanyl by over 100% during the 30 hour time frame. 
The  temperature  increase  of  the  skin  surface  produced  by  the  ThermaCare  patch 
(approximately  1.5  º  C,  see  Figure  2)  was  determined  to  be  a  unsafe  amount  of  localized 
heating for patients using the ThermaCare heat pad.  Results from this simulation are relevant 
to numerous clinical cases where patients experiencing “breakthrough” pain apply heating pads 
to  their  fentanyl  skin  patches  in  order  to  obtain  a  higher  dose  more  quickly.    However,  as 
demonstrated with this simulation, addition of a heating pad can drastically elevate fentanyl 
dose into the bloodstream and may result in the patient experiencing negative side effects and 
even death.  Figures  5-6 describe two relevant simulations in regards to using a heat pad: 
ThermaCare heat pad applied at the beginning of patch use (where heating lasts 8 hours) and 
continuous application of a ThermaCare pad over the 30 hour use of the patch, respectively.  
The concentration profile of fentanyl in the blood is described by Figure 7 for the later case. 
Patients who apply heating pads directly over the transdermal patch often do so to alleviate 
“break through” pain without understanding of the potential side effects that they may induce.  
Still  other  patients  treat  “break  through”  pain  by  applying  multiple  patches  which  multiplies 
fentanyl  blood  concentration  by  the  number  of  patches  applied.    Despite  manufacturer, 
physician, and FDA warnings about applied local heat and application of additional patches, 
many accidental overdoses have been documented, often resulting in death of the patients.  
This  computer  model  could  be  used  to  developed  more  quantitative  guidelines  specific  to 
individual  patients  (considering  individual  differences  in  the  above  mentioned  variables  that 
affect reaction to fentanyl doses; age, weight, duration of fentanyl use, etc.).   
 
Figure 5. Fentanyl blood concentration over 8 hours when ThermaCare heat pad is 
applied at time zero (heat pad maintains equilibrium temperature for 6 hours).  Blood 
concentration, cblood, is given mol/m
3.  Time is given in seconds. 10 
 
 
 
 
Figure 6. Fentanyl blood concentration over 8 hours while using ThermaCare heat pad 
continuously (over 30 hours).  Blood concentration, cblood, is given mol/m
3.  Time is 
given in seconds. 
 
Figure 7. Fentanyl concentration profile after 30 hours in the epidermis and dermis when 
using a ThermaCare heat pad. 
In addition to simulating the increase in fentanyl dose to a patient using a ThermaCare heat pad 
over different durations of time, this computer model was also used to simulate a patient with a 
fever (modeled at 102º F) and a patient whose patch is covered by a heating blanket.  As seen 
in  Figures  8-9,  the  elevated  body  temperature  of  a  patient  with  a  fever  resulted  in  a  40% 
increase of fentanyl in the bloodstream.  This simulation can be related to many clinical cases 
during which the patient becomes ill while using fentanyl skin patches.  Since these patches are 
used continuously (replaced every 36 to 72 hours depending on the patch), illness of a patient 
could very well affect the dose of fentanyl that they receive through the duration of the illness.  
This results of this simulation make it apparent that both manufacturers and physicians should 11 
 
 
include such cases when instructing patients on the use of fentanyl pain patches for enhanced 
safety. 
Another case of interest was that of application of a heating blanket (modeled to maintain a 
constant  temperature  of  42 °C  or  107.6 °F).
viii  As seen in  Figures  8-9,  the application of a 
heating blanket placed over the patient resulted in the highest increase of fentanyl blood 
concentration of the heating situations considered in this study with a 180% increase of fentanyl 
blood concentration when compared to the no heat case.  Heating blankets placed over patients 
using fentanyl patches can lead to very dangerous situations.  In one such documented case, a 
heating blanket was placed over a patient in the hospital.  The applied heat resulted in a spike in 
fentanyl blood concentration that caused the patient to go into respiratory failure.  Fortunately, in 
this  particular  case,  the  patient’s  physicians  realized  the  cause  and  promptly  removed  the 
heating blanket and the patient recovered from the incident.
ix  Documented clinical cases similar 
to this incident not only stress the potential dangers of fentanyl pain patches when heat is 
applied, but also stress the importance of building a simulation that can model and predict such 
dangerous heating situations.       
 
Figure 8. Comparison of fentanyl blood concentration over time with no heat, fever, 
ThermaCare heat pad, and heating blanket simulations. 
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Figure 9.  Increase in fentanyl blood concentrations in different heating situations (fever, 
heating blanket, and ThermaCare heat pad.  Increases are reported as percent increases 
as compared to the simulation with no applied heat. 
Sensitivity Analysis 
Our sensitivity analysis with respect to a decrease and increase in conductivity, specific heat, 
and  density  values  yielded  no  major  change  in  the  values  of  average  concentration  and 
temperature.  The average concentration was calculated at the end of the simulation (6 hours, 
or 21600 seconds); however, temperature of the entire area converges to a single value at this 
time point.  Therefore, a point where there was the largest gradient in temperature throughout 
the  depth  of  the  region  of  interest  was  chosen  for  the  sensitivity  analysis  (400  seconds).  
Sensitivity  analyses  of  the  various  parameters  involved  (thermal  conductivity,  density,  and 
specific heat of the drug) were performed according to their likely ranges of variation as reported 
in the literature.  No significant changes in either skin temperature or drug concentration were 
observed  for  such  variations.  Fifteen  percent  variability  for  thermal  conductivity  (k)  and  5% 
variability for density (ρ) and specific heat (cp) were chosen given these observed ranges as 
reported in the literature.
x  The sensitivity analysis with respect to temperature is seen in Figure 
10.  As shown in Figure 10, +/-15% variability in thermal conductivity (k) nor +/-5% variability in 
density (ρ) and specific heat (cp), respectively, caused a significant deviation in the calculated 
average temperature at the 400 second time point (approximately 310K).  Figure 11 illustrates 
the sensitivity analysis for concentration. As displayed in Figure 11, +/-15% variability in thermal 
conductivity (k) nor +/-5% variability in density (ρ) and specific heat (cp), respectively, caused a 
significant  deviation  in  the  calculated  average  concentration  at  the  6  hour  time  point 
(approximately 1.85 mol/m
3). 
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Figure 10.  Sensitivity analysis for temperature.  Thermal conductivity (k) was varied by 
15%, while density (ρ) and specific heat (cp) were varied by 5%.  Average temperature 
was calculated at the 400 second time point. 
 
Figure 11.  Sensitivity analysis for concentration.  Thermal conductivity (k) was varied by 
15%, while density (ρ) and specific heat (cp) were varied by 5%.  Average concentration 
was calculated at the six hour time point. 
Accuracy Check 
An  accuracy  check  was  performed  to  assess  the  validity  of  our  model  using  a  completely 
separate study (results given below).  Model data shown below is similar to that in the literature.  
The  input  parameters  for  the  model  were  modified  to  simulate  the  diffusion  of scopolamine 
through  human  skin  as  explored  by  Rim et  al.
xi  Our simulation is compared to that of the 
published study with no applied heat and constant diffusivity in both cases.  This accuracy 
check verifies the data produced by the no heat model  where diffusivity is constant  against 
experimental data through the epidermis. 
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Figure 12. Scopolamine concentration profile for initial concentration of 4.4 mg/ml at 
different times. The diffusion is from an infinite vehicle.  
 
Our  model  was  verified  for  accuracy  using  data  from  the  study  by  Ashburn,  et  al.  for  an 
experiment that was separate from the data used to calibrate our model (see “Methods”).  The 
study used for verification of our model recorded blood concentration of fentanyl over a 30-hour 
period following application of a fentanyl patch, with heat applied during the first four hours, and 
then again for one hour at the 24-hour mark.  (Note that the experiment upon which our model 
was based did not include heating for the first four hours, and was conducted with a separate 
subject population.)   
 15 
 
 
 
Figure 13. Comparison of model to experimental data: fentanyl blood concentration over 
30 hours with early applied heat (first four hours) and one hour of applied heat at 24 
hours.
xii 
It  is  readily  observed  that  the  general  form  of  the  concentration  curve  generated  using  our 
model very closely resembles that of the experiment: a peak occurs at the end of early heat 
addition (4 hrs), followed by a trough period which culminates in a second spike at the beginning 
of the final heating period (24 hrs).  Comparing our peak values of 1.35ng/mL to 1.15ng/mL and 
trough values of 0.975ng/mL to .65 ng/mL, it becomes evident that the model’s data closely 
resembles the experimental data: both trough and peak values are within the correct orders of 
magnitude and are within 50% of actual values. 
It  should  be  noted  that  the  model  data  reports  slightly  higher  fentanyl  blood  concentrations 
overall, compared to experimental data.  We acknowledge that our model does not take into 
account the effects of drug degradation, which becomes a factor in fentanyl blood concentration 
at the timescales with which our model is concerned.  Furthermore, our model is designed such 
that  all  fentanyl  diffusing  through  the  bottom  of  the  dermis  layer  is  reported  in  blood 
concentration.  Both of these limitations existing in our model would account for slightly higher 
blood concentrations being reported than are found in the experimental study. 
 
Conclusions and Design Recommendations 
The motivation in undertaking this particular study was to assess the dangers of deliberate or 
accidental addition of heat to skin patches containing fentanyl.  It is evident from our findings 
that the addition of heat by either a heating pad or heating blanket dramatically increases the 
rate of drug delivery from a patch applied to the skin.  Given the myriad factors involved in 
prescribing the proper dose of fentanyl to a patient (including body weight, size, gender, amount 
of pain, response to side-effects, length of time having taken fentanyl or other related drugs, and 
other factors), as well as the many known side-effects and acknowledged toxicity of the drug, 
the importance of maintaining the prescribed dosing is realized.  Our findings reported herein 16 
 
 
indicate that the addition of heat to a fentanyl skin patch might increase the rate of drug delivery 
well into the toxic range for certain patients.  We further extrapolate from our findings that heat 
addition of any kind, such as from exercise (which may or may not be relevant considering the 
nature of the patient’s ailment), use of a sauna, or a particularly hot day, might similarly increase 
the rate of fentanyl drug delivery well above the tolerable dosage.  However, most of such cases 
are not as relevant to discussion as most fentanyl patients are not undertaking such activities 
given the nature of the conditions that require fentanyl prescription.  Since both the activities 
and prescription requirements can be quite variable from patient to patient, the development of 
this simulation could greatly benefit the manufacturer and physician by being able to give the 
patient more individualized, quantitative guidelines for safe use of their prescribed fentanyl skin 
patch.   
The negative side effects that are caused by high levels of fentanyl blood concentration pose a 
greater danger with patches that are manufactured to provide higher doses over time.  Given 
the numerous factors that govern a patient’s needed dose of fentanyl, physicians can prescribe 
patches  that  vary  in  their  intended  drug  flux  or  prescribe  the  use  of  multiple  patches 
simultaneously.  All simulations in this study were modeled with a “low dose” patch (25 µg/hr).  
However, by running many simulations it was determined that a patch that provided 80µg/hr of 
fentanyl  would  approach  the  lethal  blood  concentration  of  fentanyl  when  coupled  with  a 
ThermaCare  heating  pad.    Patches  designed  to  deliver  80µg/hr  are  currently  available  for 
patients  needing  higher  doses.    As  seen  in  Figure  14,  addition  of  a  ThermaCare  heat  pad 
causes the blood concentration to approach 2.0*10
-5 mol/m
3 over the 30 hour use period (lethal 
fentanyl blood concentration for most patients is 2.077*10
-5 mol/m
3).
xiii 
 
Figure 14. Fentanyl blood concentration for 80µg/hr patch with and without applied heat 
by a ThermaCare heat pad. 
 
In addition to using this simulation for providing such guidelines, a computer simulation could be 
used to experiment with potential designs without as much experimentation with subjects. The 
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development  of  a  transdermal  delivery  system  for  fentanyl  that  protected  patients  against 
possible  overdose  is  a  potential  goal  of  future  simulation  studies.    Despite  the  packaged 
warnings from both the companies that market the fentanyl patches and warnings from the FDA, 
overdoses still occur and are often lethal.  Accidental overdoses have also taken the lives of 
several children who placed used patches from the trash on themselves.  The development of a 
patch where patients are required to apply heat to the patch in order to obtain the necessary 
dose of fentanyl over time is a possible design that could eliminate such accidental overdoses.  
A drawback to such a design could present the problem of insufficient dose, however, which 
would be another parameter that would need to be analyzed in the severity of effect on the 
patient through clinical studies.  Additionally, the cost of such a system would likely discourage 
any company from producing such a product, given the cost of a heat pad.  For example, the 
ThermaCare  heat  pad  used  in  this  study  (maintaining  temperature  for  up  to  8  hours)  costs 
approximately three dollars.  Such a system would be financially impractical in addition to the 
inconvenience  posed  to  the  patient.    Reusable  heat  pads  (such  as  those  placed  in  the 
microwave)  could  solve  the  financial  constraint  of  a  heat-required  system,  however,  the 
inconvenience  and  potential  discomfort  that  the  patient  would  experience  when  using  the 
system  may  discourage  its  development.    Given  the  number  of  heat  pads  available  on  the 
market,  manufacturability  would  not  be  a  concern  for  implementing  this  system.    The 
drawbacks, as stated previously, would lie in the economic and user convenience and comfort, 
for a system with increased safety. 
While any redesign of the fentanyl patch would require animal and/or human clinical studies, the 
use of computer simulation as modeled in this report would drastically reduce experiment time 
and cost in such an endeavor.  Patches that contain small needles that direct fentanyl directly 
into the capillary network in the dermis could  potentially be designed in order to lessen the 
possible effects of heating on drug diffusion in the epidermis and dermis and thereby improve 
the  safety  of  the  patch.    Patches  of  this  design  would  likely  incur  a  greater  cost  to  the 
manufacturer, but such an economic constraint could provide greater safety associated with the 
product.  Despite the safety gained by reducing the effects of potential heating, such a design 
could raise other ethical questions since it would be easier to abuse by fentanyl addicts and 
would not improve the safety issue of children mistaking fentanyl skin patches as stickers and 
placing them on their bodies, resulting in overdose.   
Given the numerous negative side effects of fentanyl overdose and their severity, the addition of 
heat to such skin patches is realized given the number of health issues, accidental deaths, and 
suicides caused by these patches every year.  However, other drugs that are currently available 
in transdermal delivery systems could potentially be enhanced by applied heat where a faster 
dose is necessary.  Scopolamine, a drug used to treat motion sickness, is on such drug.  In 
order to be effective, the drug must reach a given steady state concentration in the blood at 
least an hour before the motion sickness would set in.  Since many consumers do not always 
plan  ahead  or  anticipate  motion  sickness,  a  design  that  allowed  a  faster  delivery  would  be 
beneficial for such a system.  However, scopolamine, similarly to fentanyl, can have adverse 
effects on some people when too high of a dose is given too quickly, though not as severe as 
those of fentanyl (side effects of dizziness and nausea).  Therefore, such a design would need 
to implement safety mechanisms as well as packaged warnings.  Another proposed possibility 18 
 
 
for  heat  and  diffusion  coupled  transdermal  drug  delivery  is  for  emergency  contraception, 
currently available in pill form, but advantageous when the dose of drug is administered faster to 
the bloodstream.  Again, as mentioned previously, the development of such a system would 
invariably require numerous clinical studies, but the use of a computer simulation model would 
expedite the design and experimental process of such systems.  Lastly, it should be noted that 
there is ethical concern when designing systems that require heating to be most effective.  This 
is due to the fact that advertisement of such a system may lead consumers of other transdermal 
drug delivery products to believe that applied heating is beneficial to their own system, which 
may not in fact be the case, such as that of fentanyl, and could lead to misconceptions that 
promote abuse of these patches and result in negative side effects and/or death. 
Given the potential dangers associated with fentanyl, a computer simulation of its diffusion and 
therefore delivery into the body can be an important asset for both manufacturer and physician.  
Simulations can provide manufacturers and physicians the necessary tools to provide patients 
with quantitative guidelines in hopes of improving the safety of transdermal fentanyl delivery 
systems.  The reduced time of experimentation granted by a simulation benefits the company by 
reducing costs and time to development, as well as a means to test newly conceived designs or 
safety  implements  for  the  system  before  manufacturing  them.    As  stated  previously,  this 
simulation may also be used to assess the safety and feasibility of using applied heat with other 
transdermal drug delivery systems. 
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Appendix A: Mathematical Statement of the Problem 
          T = varies*, c = .055 mol/m
3 
 
              
0, 0
cT
rr
 
 
 
 
0, 0
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zz
 
Patch size (circular) = 33.6 cm
3 
*Temperature profile as given by Figure 4. 
Figure  15.  Schematic  of  system  and  skin  with  boundary  conditions  and  appropriate 
geometry.  The hypodermis layer was not included in the COMSOL model since fentanyl 
uptake occurs in the dermis.  Not drawn to scale.   
Initial Conditions: 
Ttissue=37ºC 
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Table 1. Input 
Parameters
xiv 
 
Density (ρ)  1000 kg/m
3 
Thermal Conductivity (k)   
          Epidermis  0.21 W/(m·K) 
          Dermis  0.37 W/(m·K) 
Heat Capacity (cp)   
          Epidermis  3181.82 J/(kg·K) 
          Dermis  2846.15 J/(kg·K) 
D isotropic   
          Epidermis  3.61e-11*exp(-50/(0.90078*T)) m
2/s 
          Dermis  3.61e-11*exp(-50/(0.90078*T)) + 
400*(3.61e-11*exp(-50/(0.90078*T)) -3.61e-
11*exp(-50/(0.90078*306))) (T) m
2/s 
Reaction Rate (R)  0 mol/(m
3·s) 
[Fentanyl] at Interface  0.055 mol/m
3 
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Appendix B: Solver, Time Stepping, Mesh, and Mesh Convergence 
Analysis 
Solver 
Both the Mass and Heat Diffusion solvers in COMSOL were used for the simulations presented 
in this report.  The Direct (UMFPACK) linear system solver was used. 
Time Stepping 
Over  the  30  hour  simulations  presented  in  this  report,  time  steps  were  taken  every  1800 
seconds.  Time steps taken by solver were set to Intermediate.  Times stored in output were 
specified times. 
Mesh Convergence 
In order to determine that the solution is independent of the mesh, a mesh convergence was 
completed.    The  number  of  mesh  elements  was  varied  while  calculating  the  average 
concentration and average temperature.  These values were then plotted in order to view the 
number  of  mesh  elements  where  the  average  concentration  and  average  temperature 
converged to a value.  By completing the mesh convergence, it was determined that 3000 mesh 
elements is optimal for the model in regards to computing time. 
As  displayed  by  Figures  18-20,  temperature  values  are  accurate  for all  of  the  experimental 
meshes,  but  for  the  concentration,  the  average  concentration  converges  for  the  mesh  with 
approximately 4500 elements (Figures 16 and 21) .  However, after computing the concentration 
profile  over  the  time  frame  of  interest,  it  was  concluded  that  the  greatest  variation  in 
concentration  was  in  the  epidermis  region.    Therefore,  separate  mesh  convergences  were 
performed for subdomains 2 and 3, the dermis and the epidermis, respectively.  The final mesh 
(Figure 22) was chosen for subdomains 2 and 3 separately at the mesh element number where 
both the average concentration and temperature converged to one value.   
 
 
Figure 16.  Mesh convergence for concentration for all three subdomains (hypodermis, 
dermis, and epidermis).  
1.683
1.6835
1.684
1.6845
0 2000 4000 6000
A
v
e
r
a
g
e
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
[
m
o
l
/
m
3
]
Number of Elements
Mesh Convergence for 
Concentration22 
 
 
 
Figure 17.  Mesh convergence for temperature for all three subdomains (hypodermis, 
dermis, and epidermis).  
 
 
Figure 18.  Mesh convergence for temperature in subdomain 2 (dermis) after 600 
seconds. 
 
 
Figure 19.  Mesh convergence for concentration in subdomain 2 (dermis) after 6 hours. 
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Figure 20.   Mesh convergence for temperature in subdomain 3 (epidermis) after 600 
seconds. 
 
Figure 21.  Mesh convergence for concentration in subdomain 3 (epidermis) after six 
hours. 
 
Figure 22.  Final mesh containing a total of 3000 rectangular elements. 
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Appendix C 
Diffusivity of Fentanyl:  
   
P = KD/Δx, where:   
P = permeability; D = diffusivity; K = partition coefficient; Δx = thickness 
of diffusion layer 
K = Cp/Cs, where: 
    Cp = concentration in polymer; Cs = drug solubility in pure water 
  D = D0e
(-E/RT), where: 
        D0 = pre-exponential factor; E = activation energy of diffusion; R  
        = universal gas constant; T = temperature, Kelvins 
 
  Experimental data and known constants: 
    P37ºC = 16.8x10
3cm/hr
xv     
Cs = 0.122mg/mL
xvi     
Cp = 0.2968mg/mL     
Δx = 1.575mm 
E = 50kcal/lbmol 
R = 0.90078kcal/lbmol·K 
T = 310K 
   
  From calculations: 
    K = 2.433 
    D = 3.02x10
-11mol/m
3 
    D0 = 3.61x10
-11mol/m
3 26 
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